SCHEMBL19066895

SCHEMBL19066895

Nc1ccc(CNC(=O)NCC2Cc3cc(-c4ccc(C(=O)N5CCC(F)(F)CC5)cc4)cc(-c4ccc(F)cc4)c3O2)cn1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 5/20 0.54
▸ PAK4 O96013 2/20 0.54
▸ PAK1 Q13153 1/20 0.54
▸ ENPP2 Q13822 3/20 0.37
▸ GPR119 Q8TDV5 1/20 0.35
▸ MTOR P42345 3/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ PPIB P23284 1/20 0.34
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ KCNH2 Q12809 2/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ PRKAA2 P54646 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19066862 0.84 PAK4 (0.45) NAMPTPAK4PAK1ENPP2HDAC3
SCHEMBL20651744 0.82 NAMPT (0.58) NAMPTPAK4PAK1ENPP2MTOR
SCHEMBL19066866 0.82 NAMPT (0.78) NAMPTPAK4PAK1ENPP2MTOR
SCHEMBL19066858 0.81 PAK4 (0.44) NAMPTPAK4PAK1HDAC3HDAC1
SCHEMBL19066875 0.80 NAMPT (0.58) NAMPTPAK4PAK1ENPP2MTOR
SCHEMBL19078998 0.80 NAMPT (0.58) NAMPTPAK4PAK1ENPP2MTOR
SCHEMBL19079655 0.80 PAK4 (0.42) NAMPTPAK4PAK1GPR119HDAC3
SCHEMBL19079805 0.79 NAMPT (0.49) NAMPTPAK4PAK1HDAC1
SCHEMBL19079064 0.79 NAMPT (0.56) NAMPTPAK4PAK1ENPP2HDAC3
SCHEMBL19066892 0.77 NAMPT (0.68) NAMPTPAK4PAK1ENPP2MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10858347-B2 Multicyclic compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2020-12-08 — — US claimed
US-20190016710-A1 MULTICYCLIC COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. 2019-01-17 — — US claimed
US-10858347-B2 Multicyclic compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2020-12-08 — — US disclosed
US-10858347-B2 Multicyclic compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2020-12-08 — — US disclosed
US-20190016710-A1 MULTICYCLIC COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. 2019-01-17 — — US disclosed
US-20190016710-A1 MULTICYCLIC COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. 2019-01-17 — — US disclosed
WO-2017117447-A1 MULTICYCLIC COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2017-07-06 — — WO disclosed
WO-2017117447-A1 MULTICYCLIC COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2017-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016710-A1 MULTICYCLIC COMPOUNDS AND USES THEREOF MALT1, BCL9, BCL6 NAMPT 3853/4885PAK4 1828/4885PAK1 2595/4885
US-10858347-B2 Multicyclic compounds and uses thereof MALT1, BCL9, BCL6 NAMPT 3853/4885PAK4 1828/4885PAK1 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback